+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biotechnology & Pharmaceutical Services Outsourcing Market - Global Forecast to 2030- Product Image
Biotechnology & Pharmaceutical Services Outsourcing Market - Global Forecast to 2030- Product Image
Sale

Biotechnology & Pharmaceutical Services Outsourcing Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010907
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biotechnology & Pharmaceutical Services Outsourcing Market grew from USD 167.95 billion in 2024 to USD 188.18 billion in 2025. It is expected to continue growing at a CAGR of 11.94%, reaching USD 330.57 billion by 2030.

Outsourcing of biotechnology and pharmaceutical services has evolved from a purely cost-driven exercise into a strategic partnership that delivers specialized expertise, operational agility, and accelerated timelines. Companies increasingly rely on third-party providers to navigate complex regulatory frameworks, optimize manufacturing processes, and advance novel therapies-particularly biologics, cell and gene therapies, and precision medicine-toward commercial launch. As internal capabilities stretch to accommodate diverse pipelines, decision-makers confront the dual challenge of maintaining stringent quality standards while achieving faster time to market. Digital transformation, supply chain resiliency, and adaptive regulatory strategies have emerged as critical enablers. This executive summary delves into the transformative shifts reshaping outsourcing dynamics, assesses the cumulative impact of U.S. tariffs in 2025, and distills key segmentation, regional, and competitive insights. By weaving these perspectives together, the analysis equips leaders with a comprehensive understanding of the forces driving outsourcing strategies and sets the stage for actionable recommendations that fortify innovation, mitigate risk, and maximize return on investment.

Transformative Shifts Defining the Outsourcing Ecosystem

The outsourcing landscape is undergoing fundamental transformation as life sciences organizations shift from transactional, price-focused engagements to long-term, integrated partnerships. Providers are extending their value proposition beyond commodity services to encompass digital and data analytics platforms, enabling real-time process monitoring and predictive quality control. Advances in artificial intelligence and machine learning are also reshaping drug discovery and development workflows, accelerating candidate screening, and refining target validation. Concurrently, the proliferation of advanced therapies-such as CAR-T cell treatments and antibody drug conjugates-demands specialized manufacturing capabilities and tailored regulatory support. In response, contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) are investing heavily in flexible modular facilities and forging alliances to build end-to-end solution suites. Meanwhile, supply chain disruptions and heightened geopolitical uncertainty have underscored the need for diversified sourcing strategies and near-shoring options. Ultimately, these shifts are forging a more collaborative ecosystem, where co-development, shared risk models, and outcome-based contracts define the next generation of outsourcing engagements.

Cumulative Impact of United States Tariffs in 2025

The introduction of new U.S. tariffs in 2025 on active pharmaceutical ingredients, specialized equipment, and key raw materials has reverberated across global supply chains. Manufacturers face elevated input costs, prompting sponsors and service providers to reassess sourcing footprints and negotiate alternative supplier agreements. Many organizations are accelerating regional diversification-spreading critical operations across North America, Europe, and Asia-Pacific-to mitigate tariff exposure and ensure continuity. Moreover, heightened import duties have catalyzed investment in local capacity expansion, particularly in API and biologics production, as stakeholders seek tariff-free domestic throughput. Regulatory agencies are responding with streamlined approval pathways for technology transfers and facility inspections, reducing time-to-qualification for newly established sites. However, the cost pressures associated with tariffs are translating into more aggressive pricing negotiations and the need for greater transparency in cost structures. In essence, the 2025 U.S. tariff framework is prompting a strategic realignment of sourcing strategies, driving resilience through diversification while reinforcing the importance of robust risk management protocols.

Comprehensive Segmentation Insights Across Service, Application, and Technology

A granular view of market segmentation reveals diverse growth drivers and strategic imperatives across multiple dimensions. By service type, consulting offerings-ranging from lifecycle management to regulatory affairs-are experiencing heightened demand as sponsors navigate increasingly complex approval processes. Manufacturing services encompass advanced drug delivery systems, API production, and biologics production, the last of which spans antibody drug conjugates, cell therapy production, and vaccine production. Non-clinical services focus on bioanalytical testing, pathology & microbiology, and toxicology studies, ensuring safety and efficacy benchmarks are met before clinical entry. In parallel, R&D services cover clinical biology, genomics & proteomics, and in-vitro pharmacology, underpinning precision medicine initiatives. When examining the end-user landscape, emerging and large biotechnology companies are driving early-stage innovation, while multinational pharmaceutical companies-divided into big pharma and biopharma-leverage outsourcing to optimize global supply chains. Application-based segmentation highlights cardiovascular disease projects in angiogenesis and thrombosis alongside oncology pipelines in cell-based therapies and immunotherapies. Technological segmentation underscores the adoption of CRISPR & gene editing, including base editing and prime editing, as well as high-throughput screening through automated platforms and expansive compound libraries. Finally, therapeutic area analysis points to autoimmune disease targets like psoriasis and rheumatoid arthritis, and infectious disease programs focused on viral infections such as hepatitis and HIV. Together, these segments illustrate how sponsors and service providers tailor offerings to evolving scientific priorities and patient needs.

Key Regional Dynamics Shaping Outsourcing Strategies

Regional dynamics continue to shape outsourcing strategies as stakeholders balance cost, quality, and regulatory considerations. In the Americas, robust innovation clusters and established regulatory frameworks support seamless scaling from development to commercial manufacturing, while near-shoring trends further bolster supply chain security. Europe, Middle East & Africa presents a heterogeneous environment: Western Europe is anchored by leading CDMOs and CROs driving high-complexity biologics work, whereas emerging markets across the Middle East and Africa offer growing contract research capacity and cost arbitrage. In Asia-Pacific, government incentives and expansive manufacturing infrastructure have positioned the region as a powerhouse for both small molecule and biologics production, attracting global partnerships that leverage lower operating costs and accelerated facility commissioning. Cross-regional collaborations are increasingly common, as sponsors seek to mitigate geopolitical risk and optimize global footprint. Consequently, successful outsourcing strategies now require a nuanced understanding of each region’s regulatory regimes, talent pools, and logistical capabilities to deliver end-to-end solutions with agility and consistency.

Notable Company Strategies and Portfolio Enhancements

Industry leaders are pursuing diverse approaches to strengthen their outsourcing portfolios and differentiate service offerings. AmerisourceBergen Corporation and McKesson Corporation have expanded distribution and specialty logistics services through strategic acquisitions and joint ventures. CEVA Logistics AG and DHL International GmbH have integrated digital tracking and advanced cold-chain solutions to support temperature-sensitive biologics. Charles River Laboratories, Inc. and LabCorp have enhanced non-clinical and clinical testing capabilities, while Icon PLC and IQVIA HOLDINGS, INC. have invested in data analytics platforms to streamline trial design and patient recruitment. Concept Heidelberg GmbH and Hitachi Ltd. are pioneering high-throughput screening instrumentation, and Eurofins Scientific (Ireland) Limited has broadened bioanalytical assay offerings. Evotec SE, GenScript Biotech Corporation, and WuXi AppTec Co., Ltd. have strengthened end-to-end R&D and manufacturing services, while Dalton Pharma Services by Seikagaku Corporation focuses on specialized API process development. Curia Global, Inc., Lachman Consultant Services, Inc., Parexel International Corporation, and The Quantic Group are augmenting regulatory and lifecycle management support. These diversified moves underscore a broader trend toward integrated, technology-enabled service portfolios that address sponsors’ evolving needs from discovery through commercialization.

Actionable Recommendations for Industry Decision-Makers

Leaders should prioritize a series of targeted actions to capitalize on market opportunities and counter emergent risks. First, invest in digital platforms that integrate real-time analytics, predictive quality control, and supply chain visibility, thereby enhancing decision-making and operational efficiency. Second, diversify supplier networks across multiple geographies to mitigate tariff and geopolitical exposure, while pursuing near-shoring where regulatory incentives exist. Third, forge strategic alliances and joint development agreements with specialized providers-particularly in cell and gene therapy-to access niche expertise without significant capital outlay. Fourth, bolster regulatory intelligence by maintaining dedicated teams that track evolving guidelines and expedite dossier preparations. Fifth, adopt modular, flexible manufacturing technologies to accommodate shifts in demand and streamline technology transfer processes. Sixth, cultivate talent through cross-functional training programs, ensuring teams remain proficient in emerging modalities such as prime editing and high-throughput screening. By executing these measures in concert, organizations can build resilient, agile outsourcing models that accelerate innovation and sustain competitive advantage.

Conclusion and Strategic Outlook

In an era defined by scientific breakthroughs, regulatory complexity, and shifting geopolitical landscapes, outsourcing has become an indispensable lever for driving efficiency and innovation. The convergence of advanced therapies, digital transformation, and tariff-driven supply chain realignment is reshaping stakeholder expectations around quality, speed, and cost. By aligning segmentation strategies with regional strengths and leveraging the evolving capabilities of leading service providers, organizations can secure the agility needed to translate promising research into life-changing treatments. The insights and recommendations presented herein offer a roadmap for navigating the current environment, fortifying partnerships, and sustaining long-term growth in a dynamic marketplace.

Market Segmentation & Coverage

This research report categorizes the Biotechnology & Pharmaceutical Services Outsourcing Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Consulting Services
    • Lifecycle Management
    • Regulatory Affairs
  • Manufacturing Services
    • Advanced Drug Delivery Systems
    • API Production
    • Biologics Production
      • Antibody Drug Conjugates
      • Cell Therapy Production
      • Vaccine Production
  • Non-Clinical Services
    • Bioanalytical Testing
    • Pathology & Microbiology
    • Toxicology Studies
  • R&D Services
    • Clinical Biology
    • Genomics & Proteomics
    • In-Vitro Pharmacology
  • Biotechnology Companies
    • Emerging Biotechs
    • Large Biotechs
  • Pharmaceutical Companies
    • Multinational Companies
      • Big Pharma
      • Biopharma Companies
  • Cardiovascular Diseases
    • Angiogenesis
    • Thrombosis
  • Oncology
    • Cell-Based Therapies
    • Immunotherapies
  • CRISPR & Gene Editing
    • Base Editing
    • Prime Editing
  • High Throughput Screening
    • Automated Technology
    • Compound Libraries
  • Autoimmune Diseases
    • Psoriasis
    • Rheumatoid Arthritis
  • Infectious Diseases
    • Viral Infections
      • Hepatitis
      • HIV

This research report categorizes the Biotechnology & Pharmaceutical Services Outsourcing Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Biotechnology & Pharmaceutical Services Outsourcing Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AmerisourceBergen Corporation
  • CEVA Logistics AG
  • Charles River Laboratories, Inc.
  • Concept Heidelberg GmbH
  • Curia Global, Inc.
  • Dalton Pharma Services by Seikagaku Corporation
  • DHL International GmbH
  • Eurofins Scientific (Ireland) Limited
  • Evotec SE
  • GenScript Biotech Corporation
  • Hitachi Ltd.
  • Icon PLC
  • IQVIA HOLDINGS, INC.
  • Laboratory Corporation of America Holdings
  • Lachman Consultant Services, Inc.
  • McKesson Corporation by Aurelius Group
  • Parexel International Corporation
  • The Quantic Group
  • WuXi AppTec Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biotechnology & Pharmaceutical Services Outsourcing Market, by Service Type
8.1. Introduction
8.2. Consulting Services
8.2.1. Lifecycle Management
8.2.2. Regulatory Affairs
8.3. Manufacturing Services
8.3.1. Advanced Drug Delivery Systems
8.3.2. API Production
8.3.3. Biologics Production
8.3.3.1. Antibody Drug Conjugates
8.3.3.2. Cell Therapy Production
8.3.3.3. Vaccine Production
8.4. Non-Clinical Services
8.4.1. Bioanalytical Testing
8.4.2. Pathology & Microbiology
8.4.3. Toxicology Studies
8.5. R&D Services
8.5.1. Clinical Biology
8.5.2. Genomics & Proteomics
8.5.3. In-Vitro Pharmacology
9. Biotechnology & Pharmaceutical Services Outsourcing Market, by End User
9.1. Introduction
9.2. Biotechnology Companies
9.2.1. Emerging Biotechs
9.2.2. Large Biotechs
9.3. Pharmaceutical Companies
9.3.1. Multinational Companies
9.3.1.1. Big Pharma
9.3.1.2. Biopharma Companies
10. Biotechnology & Pharmaceutical Services Outsourcing Market, by Application
10.1. Introduction
10.2. Cardiovascular Diseases
10.2.1. Angiogenesis
10.2.2. Thrombosis
10.3. Oncology
10.3.1. Cell-Based Therapies
10.3.2. Immunotherapies
11. Biotechnology & Pharmaceutical Services Outsourcing Market, by Technology
11.1. Introduction
11.2. CRISPR & Gene Editing
11.2.1. Base Editing
11.2.2. Prime Editing
11.3. High Throughput Screening
11.3.1. Automated Technology
11.3.2. Compound Libraries
12. Biotechnology & Pharmaceutical Services Outsourcing Market, by Therapeutic Area
12.1. Introduction
12.2. Autoimmune Diseases
12.2.1. Psoriasis
12.2.2. Rheumatoid Arthritis
12.3. Infectious Diseases
12.3.1. Viral Infections
12.3.1.1. Hepatitis
12.3.1.2. HIV
13. Americas Biotechnology & Pharmaceutical Services Outsourcing Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Biotechnology & Pharmaceutical Services Outsourcing Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Biotechnology & Pharmaceutical Services Outsourcing Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AmerisourceBergen Corporation
16.3.2. CEVA Logistics AG
16.3.3. Charles River Laboratories, Inc.
16.3.4. Concept Heidelberg GmbH
16.3.5. Curia Global, Inc.
16.3.6. Dalton Pharma Services by Seikagaku Corporation
16.3.7. DHL International GmbH
16.3.8. Eurofins Scientific (Ireland) Limited
16.3.9. Evotec SE
16.3.10. GenScript Biotech Corporation
16.3.11. Hitachi Ltd.
16.3.12. Icon PLC
16.3.13. IQVIA HOLDINGS, INC.
16.3.14. Laboratory Corporation of America Holdings
16.3.15. Lachman Consultant Services, Inc.
16.3.16. McKesson Corporation by Aurelius Group
16.3.17. Parexel International Corporation
16.3.18. The Quantic Group
16.3.19. WuXi AppTec Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET MULTI-CURRENCY
FIGURE 2. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET MULTI-LANGUAGE
FIGURE 3. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LIFECYCLE MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ADVANCED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY API PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CELL THERAPY PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS PRODUCTION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NON-CLINICAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOANALYTICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PATHOLOGY & MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NON-CLINICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY R&D SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL BIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GENOMICS & PROTEOMICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY IN-VITRO PHARMACOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY R&D SERVICES, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY EMERGING BIOTECHS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LARGE BIOTECHS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MULTINATIONAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIG PHARMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOPHARMA COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MULTINATIONAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ANGIOGENESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CELL-BASED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY IMMUNOTHERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CRISPR & GENE EDITING, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BASE EDITING, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRIME EDITING, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CRISPR & GENE EDITING, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AUTOMATED TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPOUND LIBRARIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS PRODUCTION, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NON-CLINICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY R&D SERVICES, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MULTINATIONAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CRISPR & GENE EDITING, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS PRODUCTION, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NON-CLINICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY R&D SERVICES, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MULTINATIONAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CRISPR & GENE EDITING, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS PRODUCTION, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NON-CLINICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY R&D SERVICES, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MULTINATIONAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CRISPR & GENE EDITING, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 131. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 132. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2030 (USD MILLION)
TABLE 133. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 134. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS PRODUCTION, 2018-2030 (USD MILLION)
TABLE 135. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NON-CLINICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 136. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY R&D SERVICES, 2018-2030 (USD MILLION)
TABLE 137. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 139. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 140. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MULTINATIONAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 141. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 143. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 144. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 145. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CRISPR & GENE EDITING, 2018-2030 (USD MILLION)
TABLE 146. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2030 (USD MILLION)
TABLE 147. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 148. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 149. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 150. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 151. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 152. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2030 (USD MILLION)
TABLE 153. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 154. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS PRODUCTION, 2018-2030 (USD MILLION)
TABLE 155. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NON-CLINICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 156. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY R&D SERVICES, 2018-2030 (USD MILLION)
TABLE 157. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 159. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 160. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MULTINATIONAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 161. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 163. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 164. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 165. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CRISPR & GENE EDITING, 2018-2030 (USD MILLION)
TABLE 166. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2030 (USD MILLION)
TABLE 167. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 168. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 169. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 170. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS PRODUCTION, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NON-CLINICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY R&D SERVICES, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MULTINATIONAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CRISPR & GENE EDITING, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 189. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 190. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS PRODUCTION, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NON-CLINICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY R&D SERVICES, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MULTINATIONAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CRISPR & GENE EDITING, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS PRODUCTION, 2018-2030 (USD MILLION)
TABLE 217. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NON-CLINICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY R&D SERVICES, 2018-2030 (USD MILLION)
TABLE 219. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 221. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 222. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MULTINATIONAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 223. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 225. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CRISPR & GENE EDITING, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 233. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 234. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2030 (USD MILLION)
TABLE 235. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
TABLE 236. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOLOGICS PRODUCTION, 2018-2030 (USD MILLION)
TABLE 237. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NON-CLINICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 238. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY R&D SERVICES, 2018-2030 (USD MILLION)
TABLE 239. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 241. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 242. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MULTINATIONAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 243. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 245. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 246. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 247. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CRISPR & GENE EDITING, 2018-2030 (USD MILLION)
TABLE 248. CHINA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2018-2030 (USD MILLION)
TABLE

Companies Mentioned

  • AmerisourceBergen Corporation
  • CEVA Logistics AG
  • Charles River Laboratories, Inc.
  • Concept Heidelberg GmbH
  • Curia Global, Inc.
  • Dalton Pharma Services by Seikagaku Corporation
  • DHL International GmbH
  • Eurofins Scientific (Ireland) Limited
  • Evotec SE
  • GenScript Biotech Corporation
  • Hitachi Ltd.
  • Icon PLC
  • IQVIA HOLDINGS, INC.
  • Laboratory Corporation of America Holdings
  • Lachman Consultant Services, Inc.
  • McKesson Corporation by Aurelius Group
  • Parexel International Corporation
  • The Quantic Group
  • WuXi AppTec Co., Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Biotechnology and Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report by Service (Consulting, Auditing & Assessment), End-use (Pharmaceutical Companies, Biotech Companies), Region, and Segment Forecasts, 2024-2030 - Product Image

Biotechnology and Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report by Service (Consulting, Auditing & Assessment), End-use (Pharmaceutical Companies, Biotech Companies), Region, and Segment Forecasts, 2024-2030

  • Report
  • 150 Pages
  • Global
From
Pharmaceutical Services Outsourcing Market by Service, End-Use - Global Forecast 2025-2030 - Product Image

Pharmaceutical Services Outsourcing Market by Service, End-Use - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Biotechnology / Pharmaceutical Services Outsourcing - Global Strategic Business Report - Product Image

Biotechnology / Pharmaceutical Services Outsourcing - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
North America Biotechnology And Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report By Service (Consulting, Regulatory Affairs), By End Use, By Country, And Segment Forecasts, 2024 - 2030 - Product Image

North America Biotechnology And Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report By Service (Consulting, Regulatory Affairs), By End Use, By Country, And Segment Forecasts, 2024 - 2030

  • Report
  • 110 Pages
  • North America
From
Biologics Outsourcing Market - Global Forecast to 2030 - Product Image

Biologics Outsourcing Market - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.